251 related articles for article (PubMed ID: 24580083)
1. What are our pharmacotherapeutic options for MERS-CoV?
Al-Tawfiq JA; Memish ZA
Expert Rev Clin Pharmacol; 2014 May; 7(3):235-8. PubMed ID: 24580083
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of SARS/MERS CoV to interferons and other drugs based on achievable serum concentrations in humans.
Strayer DR; Dickey R; Carter WA
Infect Disord Drug Targets; 2014; 14(1):37-43. PubMed ID: 25019238
[TBL] [Abstract][Full Text] [Related]
3. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
Nascimento Junior JAC; Santos AM; Quintans-Júnior LJ; Walker CIB; Borges LP; Serafini MR
Expert Opin Ther Pat; 2020 Aug; 30(8):567-579. PubMed ID: 32429703
[TBL] [Abstract][Full Text] [Related]
4. Broad-spectrum coronavirus antiviral drug discovery.
Totura AL; Bavari S
Expert Opin Drug Discov; 2019 Apr; 14(4):397-412. PubMed ID: 30849247
[TBL] [Abstract][Full Text] [Related]
5. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.
Yao TT; Qian JD; Zhu WY; Wang Y; Wang GQ
J Med Virol; 2020 Jun; 92(6):556-563. PubMed ID: 32104907
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy.
Momattin H; Mohammed K; Zumla A; Memish ZA; Al-Tawfiq JA
Int J Infect Dis; 2013 Oct; 17(10):e792-8. PubMed ID: 23993766
[TBL] [Abstract][Full Text] [Related]
8. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.
Coleman CM; Sisk JM; Mingo RM; Nelson EA; White JM; Frieman MB
J Virol; 2016 Oct; 90(19):8924-33. PubMed ID: 27466418
[TBL] [Abstract][Full Text] [Related]
9. Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model.
de Wilde AH; Falzarano D; Zevenhoven-Dobbe JC; Beugeling C; Fett C; Martellaro C; Posthuma CC; Feldmann H; Perlman S; Snijder EJ
Virus Res; 2017 Jan; 228():7-13. PubMed ID: 27840112
[TBL] [Abstract][Full Text] [Related]
10. Elucidating the Drug Repurposing Spectra of COVID-19 with its Analogues SARS and MERS.
Mishra J; Prasun C; Sahoo PK; Nair MS
Mini Rev Med Chem; 2021; 21(20):3191-3202. PubMed ID: 33632095
[TBL] [Abstract][Full Text] [Related]
11. The Potential of Glycyrrhizinate in the Management of COVID-19: A Systematic Review of the Efficacy and Safety of Glycyrrhizin Preparations in the Treatment of SARS and MERS.
Li H; Hu Y; Tang H; Li S; Ding H; Zhai S; Zhao R
Am J Chin Med; 2020; 48(7):1539-1552. PubMed ID: 33202150
[TBL] [Abstract][Full Text] [Related]
12. Current views on the potentials of convalescent plasma therapy (CPT) as Coronavirus disease 2019 (COVID-19) treatment: A systematic review and meta-analysis based on recent studies and previous respiratory pandemics.
Aviani JK; Halim D; Soeroto AY; Achmad TH; Djuwantono T
Rev Med Virol; 2021 Nov; 31(6):e2225. PubMed ID: 33621405
[TBL] [Abstract][Full Text] [Related]
13. Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV).
Al-Tawfiq JA; Memish ZA
Expert Rev Anti Infect Ther; 2017 Mar; 15(3):269-275. PubMed ID: 27937060
[TBL] [Abstract][Full Text] [Related]
14. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis.
Li H; Chen C; Hu F; Wang J; Zhao Q; Gale RP; Liang Y
Leukemia; 2020 Jun; 34(6):1503-1511. PubMed ID: 32372026
[TBL] [Abstract][Full Text] [Related]
15. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Martinez MA
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis of Middle East respiratory syndrome coronavirus.
van den Brand JM; Smits SL; Haagmans BL
J Pathol; 2015 Jan; 235(2):175-84. PubMed ID: 25294366
[TBL] [Abstract][Full Text] [Related]
17. SARS and MERS: recent insights into emerging coronaviruses.
de Wit E; van Doremalen N; Falzarano D; Munster VJ
Nat Rev Microbiol; 2016 Aug; 14(8):523-34. PubMed ID: 27344959
[TBL] [Abstract][Full Text] [Related]
18. Antivirals for Respiratory Viral Infections: Problems and Prospects.
Liu Q; Zhou YH; Ye F; Yang ZQ
Semin Respir Crit Care Med; 2016 Aug; 37(4):640-6. PubMed ID: 27486742
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the potential impact of targeted vaccination strategies against severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) outbreaks in the healthcare setting.
Abdirizak F; Lewis R; Chowell G
Theor Biol Med Model; 2019 Oct; 16(1):16. PubMed ID: 31587665
[TBL] [Abstract][Full Text] [Related]
20. TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection.
Iwata-Yoshikawa N; Okamura T; Shimizu Y; Hasegawa H; Takeda M; Nagata N
J Virol; 2019 Mar; 93(6):. PubMed ID: 30626688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
